Physostigmine

Identification

Summary

Physostigmine is a cholinesterase inhibitor used to treat glaucoma and anticholinergic toxicity.

Generic Name
Physostigmine
DrugBank Accession Number
DB00981
Background

A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 275.3461
Monoisotopic: 275.163376931
Chemical Formula
C15H21N3O2
Synonyms
  • Eserine
  • Physostigmine
  • Physostol
External IDs
  • MCV-4484
  • NIH 10421

Pharmacology

Indication

For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAnticholinergic syndrome•••••••••••••••••••••• ••••••••
Treatment ofAnticholinergic syndrome•••••••••••••••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia.

Mechanism of action

Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse.

TargetActionsOrganism
AAcetylcholinesterase
inhibitor
Humans
UNeuronal acetylcholine receptor subunit alpha-4Not AvailableHumans
UNeuronal acetylcholine receptor subunit beta-2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Quickly hydrolyzed by cholinesterases

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain.

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololPhysostigmine may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Physostigmine is combined with Acetylcholine.
AclidiniumPhysostigmine may increase the neuromuscular blocking activities of Aclidinium.
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Physostigmine.
AmifampridineThe risk or severity of adverse effects can be increased when Physostigmine is combined with Amifampridine.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Physostigmine salicylate2046ZRO9VU57-64-7HZOTZTANVBDFOF-PBCQUBLHSA-N
Physostigmine SulfateG63V2J2N7164-47-1YYBNDIVPHIWTPK-KYJQVDHRSA-N
International/Other Brands
Antilirium
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AnticholiumInjection0.4 mg/1mLIntravenousProvepharm Inc.2023-10-05Not applicableUS flag
Antilirium Inj 1mg/mlLiquid1 mg / mLIntramuscular; IntravenousForest Laboratories1975-12-311998-07-07Canada flag
Physostigmine SalicylateInjection1 mg/1mLIntravenousA-S Medication Solutions2010-08-10Not applicableUS flag
Physostigmine SalicylateInjection1 mg/1mLIntravenousAkorn2010-08-10Not applicableUS flag
Physostigmine SalicylateInjection1 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2019-12-22Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AnticholiumPhysostigmine salicylate (0.4 mg/1mL)InjectionIntravenousProvepharm Inc.2023-10-05Not applicableUS flag
Physostigmine SalicylatePhysostigmine salicylate (1 mg/1mL)InjectionIntravenousHenry Schein, Inc.2022-01-13Not applicableUS flag
Physostigmine SalicylatePhysostigmine salicylate (1 mg/1mL)InjectionIntravenousA-S Medication Solutions2010-08-10Not applicableUS flag
Physostigmine SalicylatePhysostigmine salicylate (1 mg/1mL)InjectionIntravenousAkorn2010-08-10Not applicableUS flag
Physostigmine SalicylatePhysostigmine salicylate (1 mg/1mL)InjectionIntravenousHF Acquisition Co LLC, DBA HealthFirst2019-12-22Not applicableUS flag

Categories

ATC Codes
S01EB05 — PhysostigmineV03AB19 — Physostigmine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrroloindoles. These are compounds containing a pyrroloindole moiety, which is a tricyclic heterocycle which consists of a pyrrole ring fused to an indole. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Indole is a bicyclic compound consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Pyrroloindoles
Direct Parent
Pyrroloindoles
Alternative Parents
Indoles / Dialkylarylamines / N-alkylpyrrolidines / Benzenoids / Pyrroles / Carbamate esters / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Dialkylarylamine / Hydrocarbon derivative / Indole / N-alkylpyrrolidine
show 9 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carbamate ester, indole alkaloid (CHEBI:27953) / Alkaloids, Pyrroloindole alkaloids (C06535)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
9U1VM840SP
CAS number
57-47-6
InChI Key
PIJVFDBKTWXHHD-HIFRSBDPSA-N
InChI
InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1
IUPAC Name
(3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-methylcarbamate
SMILES
[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C

References

Synthesis Reference

Edward J. Glamkowski, Barbara E. Kurys, "4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof." U.S. Patent US5081117, issued September, 1978.

US5081117
General References
Not Available
Human Metabolome Database
HMDB0015116
KEGG Drug
D00196
KEGG Compound
C06535
PubChem Compound
5983
PubChem Substance
46506998
ChemSpider
5763
BindingDB
50222010
RxNav
8299
ChEBI
27953
ChEMBL
CHEMBL94
ZINC
ZINC000091689892
Therapeutic Targets Database
DAP000561
PharmGKB
PA450957
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Physostigmine
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAnticholinergics Toxicity1
3CompletedTreatmentPostoperative pain1
3Unknown StatusTreatmentCAM-ICU Diagnosed Delirium / Suspected Delirium After Elective or Emergency Heart Surgery1
0CompletedBasic ScienceResistance, Insulin1
Not AvailableCompletedOtherSchizophrenia / Smoking1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amend
  • Hope Pharmaceuticals
  • Hospira Inc.
  • Nycomed Inc.
  • Taylor Pharmaceuticals
Dosage Forms
FormRouteStrength
InjectionIntravenous0.4 mg/1mL
Injection, solutionIntramuscular; Intravenous2 mg/5ml
LiquidIntramuscular; Intravenous1 mg / mL
Injection, solutionIntramuscular; Intravenous1 MG/ML
InjectionIntravenous1 mg/1mL
Prices
Unit descriptionCostUnit
Physostigmine salicyl cryst39.48USD g
Physostigmine 1 mg/ml ampul2.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105.5 °CPhysProp
water solubility7760 mg/LNot Available
logP1.58HANSCH,C ET AL. (1995)
pKa6.12MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.992 mg/mLALOGPS
logP1.8ALOGPS
logP2.23Chemaxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.77Chemaxon
pKa (Strongest Basic)6.59Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area44.81 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity78.4 m3·mol-1Chemaxon
Polarizability30.63 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9975
Caco-2 permeable+0.5804
P-glycoprotein substrateSubstrate0.6631
P-glycoprotein inhibitor INon-inhibitor0.5442
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.7046
CYP450 2C9 substrateNon-substrate0.7838
CYP450 2D6 substrateNon-substrate0.6455
CYP450 3A4 substrateSubstrate0.7321
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9232
BiodegradationNot ready biodegradable0.8652
Rat acute toxicity4.7557 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9066
hERG inhibition (predictor II)Non-inhibitor0.8397
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.24 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-03ea-3290000000-ff0ad85b80701aa56609
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-001j-1590000000-508da23acfe2c8a2f568
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00ea-6790000000-c7dad12610a8d73fb915
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-03dj-2900000000-b9d164a9a3afaf8a17cf
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00or-0090000000-1f322550abc600bd72a9
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0490000000-e4a06a93b3b18d738157
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0900000000-d9ddac609ada184032ac
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-0900000000-ef8f7c2ddbdba70fe1d3
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01ot-0900000000-daf3030c2c85de1db72e
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-014i-0090000000-8a9155530ad88f483e2e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dj-2900000000-b9d164a9a3afaf8a17cf
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0090000000-f47134d3e6cae5398bc6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0aor-9080000000-80f2da2f655f5d33b66b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-2090000000-929ecb20686b0ff771e3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0290000000-de0dbad74371c4ea3980
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-1090000000-5529de0d9e5d3ad788b0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-5950000000-cb6605be61151ac2ba7a
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-175.2022542
predicted
DarkChem Lite v0.1.0
[M-H]-170.2063715
predicted
DarkChem Lite v0.1.0
[M-H]-174.9797542
predicted
DarkChem Lite v0.1.0
[M-H]-175.4334542
predicted
DarkChem Lite v0.1.0
[M-H]-160.67613
predicted
DeepCCS 1.0 (2019)
[M+H]+176.9014542
predicted
DarkChem Lite v0.1.0
[M+H]+167.6393513
predicted
DarkChem Lite v0.1.0
[M+H]+176.5107542
predicted
DarkChem Lite v0.1.0
[M+H]+176.7883542
predicted
DarkChem Lite v0.1.0
[M+H]+163.03413
predicted
DeepCCS 1.0 (2019)
[M+Na]+175.6092542
predicted
DarkChem Lite v0.1.0
[M+Na]+176.1277542
predicted
DarkChem Lite v0.1.0
[M+Na]+176.1497542
predicted
DarkChem Lite v0.1.0
[M+Na]+175.4687542
predicted
DarkChem Lite v0.1.0
[M+Na]+169.89052
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details
1. Acetylcholinesterase
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Nguyen PV, Aniksztejn L, Catarsi S, Drapeau P: Maturation of neuromuscular transmission during early development in zebrafish. J Neurophysiol. 1999 Jun;81(6):2852-61. [Article]
  2. Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hanninen O: Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology. 1999 Jun 15;134(2-3):169-78. [Article]
  3. Blasina MF, Faria AC, Gardino PF, Hokoc JN, Almeida OM, de Mello FG, Arruti C, Dajas F: Evidence for a noncholinergic function of acetylcholinesterase during development of chicken retina as shown by fasciculin. Cell Tissue Res. 2000 Feb;299(2):173-84. [Article]
  4. Monnet-Tschudi F, Zurich MG, Schilter B, Costa LG, Honegger P: Maturation-dependent effects of chlorpyrifos and parathion and their oxygen analogs on acetylcholinesterase and neuronal and glial markers in aggregating brain cell cultures. Toxicol Appl Pharmacol. 2000 Jun 15;165(3):175-83. [Article]
  5. Bolognesi ML, Andrisano V, Bartolini M, Minarini A, Rosini M, Tumiatti V, Melchiorre C: Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors. J Med Chem. 2001 Jan 4;44(1):105-9. [Article]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Curator comments
noncompetitive antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Curator comments
noncompetitive antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 02, 2024 22:47